Janus Henderson Group PLC boosted its stake in shares of AstraZeneca plc (NYSE:AZN) by 5,754.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 726,599 shares of the company’s stock after acquiring an additional 714,187 shares during the quarter. Janus Henderson Group PLC’s holdings in AstraZeneca were worth $24,617,000 as of its most recent SEC filing.
Other institutional investors also recently added to or reduced their stakes in the company. WFG Advisors LP increased its stake in shares of AstraZeneca by 36.0% in the second quarter. WFG Advisors LP now owns 3,716 shares of the company’s stock valued at $127,000 after buying an additional 984 shares in the last quarter. Bronfman E.L. Rothschild L.P. increased its stake in shares of AstraZeneca by 71.2% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 4,252 shares of the company’s stock valued at $145,000 after buying an additional 1,769 shares in the last quarter. First Interstate Bank increased its stake in shares of AstraZeneca by 10.3% in the second quarter. First Interstate Bank now owns 5,127 shares of the company’s stock valued at $175,000 after buying an additional 480 shares in the last quarter. Quadrant Capital Group LLC increased its stake in shares of AstraZeneca by 18.4% in the second quarter. Quadrant Capital Group LLC now owns 5,437 shares of the company’s stock valued at $147,000 after buying an additional 846 shares in the last quarter. Finally, Affinity Wealth Management acquired a new stake in shares of AstraZeneca in the second quarter valued at $204,000. Hedge funds and other institutional investors own 14.75% of the company’s stock.
AZN has been the subject of a number of research reports. BMO Capital Markets initiated coverage on AstraZeneca in a research note on Wednesday, September 6th. They issued an “outperform” rating and a $38.00 target price for the company. Sanford C. Bernstein upgraded AstraZeneca from a “market perform” rating to an “outperform” rating and raised their target price for the company from $30.00 to $39.00 in a research note on Friday, September 22nd. Natixis upgraded AstraZeneca from a “neutral” rating to a “buy” rating in a research note on Wednesday, September 6th. Argus restated a “buy” rating and issued a $35.00 target price on shares of AstraZeneca in a research note on Friday, September 1st. Finally, Citigroup upgraded AstraZeneca to a “buy” rating in a research note on Wednesday, October 18th. Four investment analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $34.20.
AstraZeneca (NYSE:AZN) last posted its quarterly earnings results on Thursday, November 9th. The company reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.55. The business had revenue of $6.23 billion for the quarter, compared to analysts’ expectations of $6 billion. AstraZeneca had a return on equity of 34.02% and a net margin of 15.90%. The firm’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter last year, the business earned $1.32 earnings per share. equities analysts forecast that AstraZeneca plc will post 1.87 EPS for the current year.
WARNING: This report was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://www.com-unik.info/2017/12/22/astrazeneca-plc-azn-holdings-lifted-by-janus-henderson-group-plc.html.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).
What are top analysts saying about AstraZeneca? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AstraZeneca and related companies.